First US Clinical Trial of Cannabinoid Supplements for Traumatic Brain Injury


The first clinical study (NCT03826368) in the US to assess the effectiveness of plant-derived cannabinoid supplements for recovery from traumatic brain injury will begin in Colorado. The supplements that will be studied are derived from a hemp strain that is a blend with less psychoactive effect than other strains. This strain was created and marketed as an option for pediatric patients with medically refractory epilepsy using medical marijuana. 

The year-long study of adults 18 to 55 years of age will analyze quantitative EEG brain activity and a cannabinoid-sensitive salivary biomarker in 40 subjects with mild traumatic brain injury and control subjects who take hemp-derived supplements (eg, phytocannabinoids) on a regular basis.

“There are currently no effective treatments for traumatic brain injury or chronic traumatic encephalopathy, but phytocannabinoids may be a good candidate, based on the established science of anti-inflammatory and neuroprotective mechanisms,” said Chloe Villano, president and founder of Clover Leaf University.   

New Drug Application Novel for Oral Fumarate Accepted by Food and Drug Administration

Previous News Article

Deep Brain Stimulator for Medically-Refractory Epilepsy Now Available in US

Next News Article
This Month's Issue
Sporadic Inclusion Body Myositis

Matthew Varon, MD; and Pedro M. Machado, MD, PhD

Genetic Testing in Neuromuscular Disorders

James P. Orengo, MD, PhD; and David R. Murdock, MD

Amyotrophic Lateral Sclerosis

Jonathan R. Brent, MD, PhD; and Senda Ajroud-Driss, MD